Pregabalin's Risks in Patients with Impaired Renal Function

Cardiovascular Risks

Pregabalin requires dosage reduction in patients with renal insufficiency due to its renal excretion pathway, and failure to adjust dosing can lead to drug accumulation and increased adverse effects, according to the Mayo Clinic Proceedings 2
Pregabalin is typically not recommended for patients with heart failure due to its risk of fluid retention, weight gain, and potential heart failure exacerbation, as stated by the American College of Cardiology, with a recommendation from Circulation 1
Patients with impaired renal function are particularly vulnerable to pregabalin's adverse cardiovascular effects due to decreased drug clearance and potential drug accumulation, as noted in the Mayo Clinic Proceedings 2

Patients with impaired renal function are at higher baseline risk for cognitive impairment, making the potential additive effects of pregabalin particularly concerning, according to the Journal of the American Geriatrics Society (JAGS) 3

Pregabalin requires specific dosage adjustments based on creatinine clearance, with significant reductions needed as renal function declines, as recommended by the Mayo Clinic Proceedings 2
The American Geriatrics Society Beers Criteria recommends using pregabalin with caution in older adults due to potential adverse effects, particularly in those with renal impairment, as stated in the Journal of the American Geriatrics Society (JAGS) 3
Failure to appropriately adjust pregabalin dosing in renal impairment can lead to drug accumulation and increased risk of adverse effects, including fluid retention and cognitive impairment, according to the Mayo Clinic Proceedings and Circulation 2, 1

For neuropathic pain management in patients with heart failure and renal impairment, selective serotonin reuptake inhibitors (SSRIs) may be safer alternatives, with sertraline having a particularly favorable cardiovascular profile, as recommended by Circulation 1, 4
Topical agents such as lidocaine patches offer localized pain relief without significant systemic effects, making them suitable options for patients with heart failure or renal impairment, according to the Mayo Clinic Proceedings 2
When systemic therapy is necessary, duloxetine may be considered as it does not appear to produce clinically important electrocardiographic or blood pressure changes, though dose adjustment is still required in renal impairment, as noted in the Mayo Clinic Proceedings 2

In patients with existing heart failure or renal impairment, pregabalin should be avoided when possible due to its risks of fluid retention and potential exacerbation of heart failure, as recommended by Circulation 1
If pregabalin must be used in patients with mild-to-moderate renal impairment, start with the lowest possible dose (e.g., 25-50mg daily) with careful titration and close monitoring of renal function, fluid status, and cognitive function, according to the Mayo Clinic Proceedings and Circulation 2, 1
For patients with both heart failure and renal impairment, a multidisciplinary approach involving cardiology, nephrology, and pain management specialists is recommended to optimize medication selection, as stated in Circulation 5